The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
Long-term survival outcomes in patients with ALL who were alive and disease-free 2 years after allo-HSCT
|
Although most deaths following allo-HSCT occur in the first 2 years post transplantation, long-term survivors are still at risk of late complications.1 A large, multicenter, retrospective, EBMT registry-based study assessed long-term survival and prognostic factors of late relapse in adult patients with acute leukemia who were alive and disease-free at 2 years after allo-HSCT. This analysis included 2,701 patients with ALL who underwent allo-HSCT between 2005 and 2012. Results were published in Hemasphere by Larue et al.1 |
| Key learnings |
| The 10-year probability for OS and LFS was 81.3% and 78.2%, respectively. |
| The cumulative RI and NRM at 10 years was 9.9% and 11.9%, respectively, and the probability of cGRFS at 10 years was 73.3%. |
| Patient- and disease-specific factors: Older age, transplantation in second or third CR, and advanced disease were associated with worse survival outcomes. |
| Transplant-specific factors: Transplantation from UD vs MSD, and PB grafts vs BM grafts were associated with inferior survival outcomes. The use of ATG improved OS, LFS, and NRM. |
| Relapses (31.9%) and cGvHD (27.3%) were the most common cause of late mortality. |
| These findings underscore the importance of optimizing pre-transplant strategies and the need for targeted interventions and surveillance strategies in long-term survivorship care to reduce late complications and improve survival outcomes. |
Abbreviations: ALL, acute lymphoblastic leukemia; allo-HSCT, allogeneic hematopoietic stem cell transplantation; ATG, antithymocyte globulin; BM, bone marrow; cGRFS, composite of chronic graft‐versus‐host disease‐free and relapse‐free survival; cGvHD, chronic graft-versus-host disease; CR, complete remission; EBMT, European Society for Blood and Marrow Transplantation; LFS, leukemia-free survival; MSD, matched sibling donor; NRM, non-relapse mortality; OS, overall survival; PB, peripheral blood; RI, relapse incidence; UD, unrelated donor.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
